Hims & Hers Health faces a securities fraud class action in the U.S. District Court for the Northern District of California over alleged disclosures concerning privacy practices, prescription charges and related regulatory exposure. The lawsuit, Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313 (N.D. Cal.), covers investors who purchased or acquired HIMS securities between August 4, 2025, and July 29, 2026. The complaint alleges that Hims shared consumers' health information with third-party advertising platforms, charged for prescriptions shortly after intake forms were submitted despite promising access to a medical consultation, and failed to disclose resulting regulatory scrutiny and potential fees and penalties. On July 29, 2026, the Federal Trade Commission filed a lawsuit accusing Hims of deceptive and unlawful privacy practices, including sharing sensitive health information with Snap and Meta Platforms. HIMS fell $4.32, or 14.73%, to close at $25.00 that day. Schall, Brown & Schwartz LLP said investors may contact the firm about possible lead plaintiff appointments in claims brought under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Investors have until November 2, 2026, to seek lead plaintiff status; they may also retain other counsel or take no action and remain absent class members. Kessler Topaz Meltzer & Check, LLP says it offers free case evaluations on a contingency-fee basis, with no cost or obligation to speak with an attorney.